» Articles » PMID: 37875265

HYPER: Pre-clinical Device for Spatially-confined Magnetic Particle Hyperthermia

Overview
Publisher Informa Healthcare
Specialties Oncology
Pharmacology
Date 2023 Oct 24
PMID 37875265
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Magnetic particle hyperthermia is an approved cancer treatment that harnesses thermal energy generated by magnetic nanoparticles when they are exposed to an alternating magnetic field (AMF). Thermal stress is either directly cytotoxic or increases the susceptibility of cancer cells to standard therapies, such as radiation. As with other thermal therapies, the challenge with nanoparticle hyperthermia is controlling energy delivery. Here, we describe the design and implementation of a prototype pre-clinical device, called HYPER, that achieves spatially confined nanoparticle heating within a user-selected volume and location.

Design: Spatial control of nanoparticle heating was achieved by placing an AMF generating coil (340 kHz, 0-15 mT), between two opposing permanent magnets. The relative positions between the magnets determined the magnetic field gradient (0.7 T/m-2.3 T/m), which in turn governed the volume of the field free region (FFR) between them (0.8-35 cm). Both the gradient value and position of the FFR within the AMF ([-14, 14], [-18, 18], [-30, 30]) mm are values selected by the user the graphical user interface (GUI). The software then controls linear actuators that move the static magnets to adjust the position of the FFR in 3D space based on user input. Within the FFR, the nanoparticles generate hysteresis heating; however, outside the FFR where the static field is non-negligible, the nanoparticles are unable to generate hysteresis loss power.

Verification: We verified the performance of the HYPER to design specifications by independently heating two nanoparticle-rich areas of a phantom placed within the volume occupied by the AMF heating coil.

Citing Articles

Ranking Magnetic Colloid Performance for Magnetic Particle Imaging and Magnetic Particle Hyperthermia.

Carlton H, Salimi M, Arepally N, Bentolila G, Sharma A, Bibic A Adv Funct Mater. 2025; 35(2):2412321.

PMID: 39882193 PMC: 11774450. DOI: 10.1002/adfm.202412321.


Magnetic Particle Imaging-Guided Thermal Simulations for Magnetic Particle Hyperthermia.

Carlton H, Arepally N, Healy S, Sharma A, Ptashnik S, Schickel M Nanomaterials (Basel). 2024; 14(12).

PMID: 38921935 PMC: 11206764. DOI: 10.3390/nano14121059.

References
1.
Hedayati M, Abubaker-Sharif B, Khattab M, Razavi A, Mohammed I, Nejad A . An optimised spectrophotometric assay for convenient and accurate quantitation of intracellular iron from iron oxide nanoparticles. Int J Hyperthermia. 2017; 34(4):373-381. PMC: 5871594. DOI: 10.1080/02656736.2017.1354403. View

2.
Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho C, Waldofner N . Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol. 2006; 52(6):1653-61. DOI: 10.1016/j.eururo.2006.11.023. View

3.
Yang C, Korangath P, Stewart J, Hu C, Fu W, Gruttner C . Systemically delivered antibody-labeled magnetic iron oxide nanoparticles are less toxic than plain nanoparticles when activated by alternating magnetic fields. Int J Hyperthermia. 2021; 37(3):59-75. PMC: 7810240. DOI: 10.1080/02656736.2020.1776901. View

4.
Dennis C, Ivkov R . Physics of heat generation using magnetic nanoparticles for hyperthermia. Int J Hyperthermia. 2013; 29(8):715-29. DOI: 10.3109/02656736.2013.836758. View

5.
Chandrasekharan P, Tay Z, Hensley D, Zhou X, Fung B, Colson C . Using magnetic particle imaging systems to localize and guide magnetic hyperthermia treatment: tracers, hardware, and future medical applications. Theranostics. 2020; 10(7):2965-2981. PMC: 7053197. DOI: 10.7150/thno.40858. View